Sign Up to like & get
recommendations!
1
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8001
Abstract: 8001Background: POM, a standard-of-care treatment (Tx) in RRMM, has demonstrated synergistic anti-myeloma activity with dexamethasone (DEX) and proteasome inhibitors (PIs). POM + DEX is indicated f...
read more here.
Keywords:
low dose;
dose dexamethasone;
bortezomib low;
dexamethasone ... See more keywords